-
1
-
-
79951972587
-
Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate
-
21149663 10.1200/JCO.2010.30.6829
-
Abrahamsson J, Forestier E, Heldrup J et al (2011) Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 29:310-315
-
(2011)
J Clin Oncol
, vol.29
, pp. 310-315
-
-
Abrahamsson, J.1
Forestier, E.2
Heldrup, J.3
-
2
-
-
84864372484
-
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients
-
10.1002
-
Faderl S, Ravandi F, Huang X et al (2012) Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. doi: 10.1002
-
(2012)
Cancer
-
-
Faderl, S.1
Ravandi, F.2
Huang, X.3
-
3
-
-
68449101812
-
Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-Acute myeloid leukemia 10 modified protocol
-
19557634 10.1080/10428190902964768 1:CAS:528:DC%2BD1MXnvVOns7c%3D
-
Gallegos-Castorena S, Medina-Sanson A, Gonzalez-Ramella O, Sanchez-Zubieta F, Martinez-Avalos A (2009) Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-Acute myeloid leukemia 10 modified protocol. Leuk Lymphoma 50:1132-1137
-
(2009)
Leuk Lymphoma
, vol.50
, pp. 1132-1137
-
-
Gallegos-Castorena, S.1
Medina-Sanson, A.2
Gonzalez-Ramella, O.3
Sanchez-Zubieta, F.4
Martinez-Avalos, A.5
-
4
-
-
77949361873
-
Acute leukaemias of ambiguous lineage in children: Characterization, prognosis and therapy recommendations
-
20085575 10.1111/j.1365-2141.2009.08058.x
-
Gerr H, Zimmermann M, Schrappe M et al (2010) Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol 149:84-92
-
(2010)
Br J Haematol
, vol.149
, pp. 84-92
-
-
Gerr, H.1
Zimmermann, M.2
Schrappe, M.3
-
6
-
-
65549162784
-
Improved patient survival for acute myeloid leukemia: A population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005
-
19020306 10.1182/blood-2008-09-179341 1:CAS:528:DC%2BD1MXlt1yjs7g%3D
-
Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M (2009) Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 113:3666-3672
-
(2009)
Blood
, vol.113
, pp. 3666-3672
-
-
Derolf, A.R.1
Kristinsson, S.Y.2
Andersson, T.M.3
Landgren, O.4
Dickman, P.W.5
Bjorkholm, M.6
-
7
-
-
76049086471
-
Independent prognostic factors for AML outcome
-
doi: 10.1182/asheducation-2009.1.385
-
Grimwade D, Hills RK (2009) Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009:385-395. doi: 10.1182/asheducation-2009.1.385
-
(2009)
Hematology Am Soc Hematol Educ Program.
, pp. 385-395
-
-
Grimwade, D.1
Hills, R.K.2
-
8
-
-
77956587147
-
High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia
-
20522712 10.1182/blood-2010-03-270991
-
de Jonge HJ, Valk PJ, Veeger NJ et al (2010) High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 116:1747-1754
-
(2010)
Blood
, vol.116
, pp. 1747-1754
-
-
De Jonge, H.J.1
Valk, P.J.2
Veeger, N.J.3
-
9
-
-
16544369516
-
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia
-
DOI 10.1056/NEJMoa031046
-
Bullinger L, Dohner K, Bair E et al (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605-1616 (Pubitemid 38501163)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.16
, pp. 1605-1616
-
-
Bullinger, L.1
Dohner, K.2
Bair, E.3
Frohling, S.4
Schlenk, R.F.5
Tibshirani, R.6
Dohner, H.7
Pollack, J.R.8
-
10
-
-
0031039243
-
The biology of vascular endothelial growth factor
-
DOI 10.1210/er.18.1.4
-
Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25 (Pubitemid 27076453)
-
(1997)
Endocrine Reviews
, vol.18
, Issue.1
, pp. 4-25
-
-
Ferrara, N.1
Davis-Smyth, T.2
-
11
-
-
12344274486
-
The biology of vascular endothelial growth factors
-
DOI 10.1016/j.cardiores.2004.12.002, PII S0008636304005498
-
Tammela T, Enholm B, Alitalo K, Paavonen K (2005) The biology of vascular endothelial growth factors. Cardiovasc Res 65:550-563 (Pubitemid 40138976)
-
(2005)
Cardiovascular Research
, vol.65
, Issue.3
, pp. 550-563
-
-
Tammela, T.1
Enholm, B.2
Alitalo, K.3
Paavonen, K.4
-
12
-
-
0031011529
-
Proteolytic processing regulates receptor specificity and activity of VEGF-C
-
DOI 10.1093/emboj/16.13.3898
-
Joukov V, Sorsa T, Kumar V et al (1997) Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16:3898-3911 (Pubitemid 27281006)
-
(1997)
EMBO Journal
, vol.16
, Issue.13
, pp. 3898-3911
-
-
Joukov, V.1
Sorsa, T.2
Kumar, V.3
Jeltsch, M.4
Claesson-Welsh, L.5
Cao, Y.6
Saksela, O.7
Kalkkinen, N.8
Alitalo, K.9
-
13
-
-
40849088142
-
Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia
-
DOI 10.1016/j.leukres.2007.08.010, PII S0145212607003232
-
Hou HA, Chou WC, Lin LI et al (2008) Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 32:904-912 (Pubitemid 351392041)
-
(2008)
Leukemia Research
, vol.32
, Issue.6
, pp. 904-912
-
-
Hou, H.-A.1
Chou, W.-C.2
Lin, L.-I.3
Tang, J.-L.4
Tseng, M.-H.5
Huang, C.-F.6
Yao, M.7
Chen, C.-Y.8
Tsay, W.9
Tien, H.-F.10
-
14
-
-
0036053859
-
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia
-
12094254 10.1038/sj.leu.2402534 1:CAS:528:DC%2BD38XkvFKrtrs%3D
-
Padro T, Bieker R, Ruiz S et al (2002) Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16:1302-1310
-
(2002)
Leukemia
, vol.16
, pp. 1302-1310
-
-
Padro, T.1
Bieker, R.2
Ruiz, S.3
-
15
-
-
30844444368
-
Disease-specific expression of VEGF and its receptors in AML cells: Possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML
-
DOI 10.1080/10428190500270386, PII P50091823782605
-
Hiramatsu A, Miwa H, Shikami M et al (2006) Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(1517) AML and VEGF/type2 receptor of VEGF in t(821) AML. Leuk Lymphoma 47:89-95 (Pubitemid 43101730)
-
(2006)
Leukemia and Lymphoma
, vol.47
, Issue.1
, pp. 89-95
-
-
Hiramatsu, A.1
Miwa, H.2
Shikami, M.3
Ikai, T.4
Tajima, E.5
Yamamoto, H.6
Imai, N.7
Hattori, A.8
Kyo, T.9
Watarai, M.10
Miura, K.11
Satoh, A.12
Itoh, M.13
Imamura, A.14
Mihara, H.15
Katoh, Y.16
Nitta, M.17
-
16
-
-
79953294156
-
Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia
-
21447743 10.1158/0008-5472.CAN-10-0402
-
Ter Elst A, Ma B, Scherpen FJ et al (2011) Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Cancer Res 71:2761-2771
-
(2011)
Cancer Res
, vol.71
, pp. 2761-2771
-
-
Ter Elst, A.1
Ma, B.2
Scherpen, F.J.3
-
17
-
-
73949133917
-
Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway
-
19825968 10.1093/carcin/bgp244 1:CAS:528:DC%2BD1MXhsFGhurrN
-
Chien MH, Ku CC, Johansson G et al (2009) Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 30:2005-2013
-
(2009)
Carcinogenesis
, vol.30
, pp. 2005-2013
-
-
Chien, M.H.1
Ku, C.C.2
Johansson, G.3
-
18
-
-
0030923575
-
Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia
-
Fielder W, Graeven U, Ergun S et al (1997) Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 11:1234-1237 (Pubitemid 27387298)
-
(1997)
Leukemia
, vol.11
, Issue.8
, pp. 1234-1237
-
-
Fielder, W.1
Graeven, U.2
Ergun, S.3
Verago, S.4
Kilic, N.5
Stockschlader, M.6
Hossfeld, D.K.7
-
19
-
-
40749117992
-
Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia
-
DOI 10.1016/j.leukres.2007.10.005, PII S0145212607003992
-
Liersch R, Schliemann C, Bieker R et al (2008) Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk Res 32:954-961 (Pubitemid 351389550)
-
(2008)
Leukemia Research
, vol.32
, Issue.6
, pp. 954-961
-
-
Liersch, R.1
Schliemann, C.2
Bieker, R.3
Hintelmann, H.4
Buechner, T.5
Berdel, W.E.6
Mesters, R.M.7
-
21
-
-
84876675868
-
Targeting multiple active kinase pathways in 11q23 translocated pediatric acute myeloid leukemia using a VEGFR2 antibody together with a MEK inhibitor
-
ASH abstract 3626
-
Ter Elst A, Kampen KR, Diks SH et al (2010) Targeting multiple active kinase pathways in 11q23 translocated pediatric acute myeloid leukemia using a VEGFR2 antibody together with a MEK inhibitor. Blood, Suppl ASH abstract 3626
-
(2010)
Blood
, Issue.SUPPL.
-
-
Ter Elst, A.1
Kampen, K.R.2
Diks, S.H.3
-
22
-
-
31144466953
-
Phosphorylated KDR can be located in the nucleus of neoplastic cells
-
DOI 10.1038/sj.cr.7310012, PII 7310012
-
Blazquez C, Cook N, Micklem K, Harris AL, Gatter KC, Pezzella F (2006) Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Res 16:93-98 (Pubitemid 43129313)
-
(2006)
Cell Research
, vol.16
, Issue.1
, pp. 93-98
-
-
Blazquez, C.1
Cook, N.2
Micklem, K.3
Harris, A.L.4
Gatter, K.C.5
Pezzella, F.6
-
23
-
-
2342486598
-
Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways
-
DOI 10.1182/blood-2003-05-1634
-
Santos SC, Dias S (2004) Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103:3883-3889 (Pubitemid 38596309)
-
(2004)
Blood
, vol.103
, Issue.10
, pp. 3883-3889
-
-
Santos, S.C.R.1
Dias, S.2
-
24
-
-
0037085765
-
Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy
-
DOI 10.1182/blood.V99.6.2179
-
Dias S, Choy M, Alitalo K, Rafii S (2002) Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99:2179-2184 (Pubitemid 34525504)
-
(2002)
Blood
, vol.99
, Issue.6
, pp. 2179-2184
-
-
Dias, S.1
Choy, M.2
Alitalo, K.3
Rafii, S.4
-
25
-
-
0036841072
-
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
-
DOI 10.1002/cncr.10900
-
Aguayo A, Kantarjian HM, Estey EH et al (2002) Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95:1923-1930 (Pubitemid 35222172)
-
(2002)
Cancer
, vol.95
, Issue.9
, pp. 1923-1930
-
-
Aguayo, A.1
Kantarjian, H.M.2
Estey, E.H.3
Giles, F.J.4
Verstovsek, S.5
Manshouri, T.6
Gidel, C.7
O'Brien, S.8
Keating, M.J.9
Albitar, M.10
-
26
-
-
0036718433
-
Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients
-
De Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hahlen K, Kamps WA (2002) Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 8:2856-2861 (Pubitemid 35025730)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.9
, pp. 2856-2861
-
-
De Bont, E.S.J.M.1
Fidler, V.2
Meeuwsen, T.3
Scherpen, F.4
Hahlen, K.5
Kamps, W.A.6
-
27
-
-
60149100926
-
The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia
-
18987662 10.1038/leu.2008.300 1:CAS:528:DC%2BD1MXhs1Olsr0%3D
-
Wegiel B, Ekberg J, Talasila KM, Jalili S, Persson JL (2009) The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia. Leukemia 23:251-261
-
(2009)
Leukemia
, vol.23
, pp. 251-261
-
-
Wegiel, B.1
Ekberg, J.2
Talasila, K.M.3
Jalili, S.4
Persson, J.L.5
-
28
-
-
78650138258
-
Vascular endothelial growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia
-
20981743 10.1002/pbc.22783 1:STN:280:DC%2BC3M%2Fjt1Glsw%3D%3D
-
Kruizinga RC, de Jonge HJ, Kampen KR, Walenkamp AM, De Bont ES (2011) Vascular endothelial growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer 56:294-297
-
(2011)
Pediatr Blood Cancer
, vol.56
, pp. 294-297
-
-
Kruizinga, R.C.1
De Jonge, H.J.2
Kampen, K.R.3
Walenkamp, A.M.4
De Bont, E.S.5
-
29
-
-
36849067425
-
Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients
-
DOI 10.1111/j.1365-2141.2007.06887.x
-
Kim DH, Lee NY, Lee MH, Sohn SK, Do YR, Park JY (2008) Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol 140:71-79 (Pubitemid 350233254)
-
(2008)
British Journal of Haematology
, vol.140
, Issue.1
, pp. 71-79
-
-
Kim, D.H.1
Lee, N.Y.2
Lee, M.-H.3
Sohn, S.K.4
Do, Y.R.5
Park, J.Y.6
-
30
-
-
33745081866
-
Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
-
DOI 10.1182/blood-2005-08-3272
-
Monzo M, Brunet S, Urbano-Ispizua A et al (2006) Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 107:4871-4879 (Pubitemid 43882640)
-
(2006)
Blood
, vol.107
, Issue.12
, pp. 4871-4879
-
-
Monzo, M.1
Brunet, S.2
Urbano-Ispizua, A.3
Navarro, A.4
Perea, G.5
Esteve, J.6
Artells, R.7
Granell, M.8
Berlanga, J.9
Ribera, J.M.10
Bueno, J.11
Llorente, A.12
Guardia, R.13
Tormo, M.14
Torres, P.15
Nomdedeu, J.F.16
Montserrat, E.17
Sierra, J.18
-
31
-
-
38449106376
-
Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis
-
Debrah AY, Mand S, Toliat MR et al (2007) Plasma vascular endothelial growth Factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 77:601-608 (Pubitemid 351844277)
-
(2007)
American Journal of Tropical Medicine and Hygiene
, vol.77
, Issue.4
, pp. 601-608
-
-
Debrah, A.Y.1
Mand, S.2
Toliat, M.R.3
Marfo-Debrekyei, Y.4
Batsa, L.5
Nurnberg, P.6
Lawson, B.7
Adjei, O.8
Hoerauf, A.9
Pfarr, K.10
-
32
-
-
8444239305
-
VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer
-
DOI 10.1016/j.lungcan.2004.04.037, PII S0169500204002053
-
Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293-298 (Pubitemid 39487303)
-
(2004)
Lung Cancer
, vol.46
, Issue.3
, pp. 293-298
-
-
Koukourakis, M.I.1
Papazoglou, D.2
Giatromanolaki, A.3
Bougioukas, G.4
Maltezos, E.5
Siviridis, E.6
-
33
-
-
0037442985
-
Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter
-
Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812-816 (Pubitemid 36231981)
-
(2003)
Cancer Research
, vol.63
, Issue.4
, pp. 812-816
-
-
Stevens, A.1
Soden, J.2
Brenchley, P.E.3
Ralph, S.4
Ray, D.W.5
-
34
-
-
38949171393
-
Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia
-
DOI 10.1158/1078-0432.CCR-07-1821
-
de Jonge HJ, Weidenaar AC, Ter Elst A et al (2008) Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res 14:924-930 (Pubitemid 351231177)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.3
, pp. 924-930
-
-
De Jonge, H.J.M.1
Weidenaar, A.C.2
Ter Elst, A.3
Boezen, H.M.4
Scherpen, F.J.G.5
Bouma-Ter Steege, J.C.A.6
Kaspers, G.J.L.7
Goemans, B.F.8
Creutzig, U.9
Zimmermann, M.10
Kamps, W.A.11
De Bont, E.S.J.M.12
-
35
-
-
82455211264
-
Identifying causal rare variants of disease through family-based analysis of Genetics Analysis Workshop 17 data set
-
10.1186/1753-6561-5-S9-S21 22373204 10.1186/1753-6561-5-S9-S21
-
Yip W, De G, Raby BA et al (2011) Identifying causal rare variants of disease through family-based analysis of Genetics Analysis Workshop 17 data set. BMC Proceedings 5(Suppl 9):S21. doi: 10.1186/1753-6561-5-S9-S21
-
(2011)
BMC Proceedings
, vol.5
, Issue.SUPPL. 9
, pp. 21
-
-
Yip, W.1
De, G.2
Raby, B.A.3
-
36
-
-
77953494817
-
Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head
-
20215856 10.3858/emm.2010.42.5.039 1:CAS:528:DC%2BC3cXnt1Gnsr4%3D
-
Hong JM, Kim TH, Kim HJ, Park EK, Yang EK, Kim SY (2010) Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head. Exp Mol Med 42:376-385
-
(2010)
Exp Mol Med
, vol.42
, pp. 376-385
-
-
Hong, J.M.1
Kim, T.H.2
Kim, H.J.3
Park, E.K.4
Yang, E.K.5
Kim, S.Y.6
-
37
-
-
0035074279
-
Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts
-
DOI 10.1089/152581601750098291
-
Foss B, Mentzoni L, Bruserud O (2001) Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts. J Hematother Stem Cell Res 10:81-93 (Pubitemid 32236687)
-
(2001)
Journal of Hematotherapy and Stem Cell Research
, vol.10
, Issue.1
, pp. 81-93
-
-
Foss, B.1
Mentzoni, L.2
Bruserud, O.3
-
38
-
-
33645000697
-
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line
-
15962006 10.1038/sj.cdd.4401698 1:CAS:528:DC%2BD2MXht1yktbrP
-
Coppola S, Narciso L, Feccia T et al (2006) Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. Cell Death Differ 13:61-74
-
(2006)
Cell Death Differ
, vol.13
, pp. 61-74
-
-
Coppola, S.1
Narciso, L.2
Feccia, T.3
-
39
-
-
0036530301
-
165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition
-
DOI 10.1182/blood.V99.7.2532
-
Dias S, Shmelkov SV, Lam G, Rafii S (2002) VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99:2532-2540 (Pubitemid 34525442)
-
(2002)
Blood
, vol.99
, Issue.7
, pp. 2532-2540
-
-
Dias, S.1
Shmelkov, S.V.2
Lam, G.3
Rafii, S.4
-
40
-
-
53149084152
-
Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
-
18386162 10.1007/s12192-008-0035-3 1:CAS:528:DC%2BD1cXhtV2qsbrI
-
Flandrin P, Guyotat D, Duval A et al (2008) Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 13:357-364
-
(2008)
Cell Stress Chaperones
, vol.13
, pp. 357-364
-
-
Flandrin, P.1
Guyotat, D.2
Duval, A.3
-
41
-
-
19444376495
-
HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun
-
DOI 10.1016/j.exphem.2005.03.009, PII S0301472X05001335
-
Schepers H, Geugien M, van der Toorn M et al (2005) HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp Hematol 33:660-670 (Pubitemid 40725832)
-
(2005)
Experimental Hematology
, vol.33
, Issue.6
, pp. 660-670
-
-
Schepers, H.1
Geugien, M.2
Van Der Toorn, M.3
Bryantsev, A.L.4
Kampinga, H.H.5
Eggen, B.J.L.6
Vellenga, E.7
-
42
-
-
33947642080
-
Autocrine VEFG loops, signaling pathways, and acute leukemia regulation
-
DOI 10.1080/10428190601064720, PII 773541839
-
Fragoso R, Elias AP, Dias S (2007) Autocrine VEGF loops, signaling pathways, and acute leukemia regulation. Leuk Lymphoma 48:481-488 (Pubitemid 46487754)
-
(2007)
Leukemia and Lymphoma
, vol.48
, Issue.3
, pp. 481-488
-
-
Fragoso, R.1
Elias, A.P.2
Dias, S.3
-
43
-
-
33750568635
-
T(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt
-
DOI 10.1111/j.1365-2141.2006.06372.x
-
Imai N, Shikami M, Miwa H et al (2006) t(821) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. Br J Haematol 135:673-682 (Pubitemid 44674078)
-
(2006)
British Journal of Haematology
, vol.135
, Issue.5
, pp. 673-682
-
-
Imai, N.1
Shikami, M.2
Miwa, H.3
Suganuma, K.4
Hiramatsu, A.5
Watarai, M.6
Satoh, A.7
Itoh, M.8
Imamura, A.9
Mihara, H.10
Nitta, M.11
-
44
-
-
70249130158
-
Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor
-
19342098 10.1016/j.leukres.2009.03.006 1:CAS:528:DC%2BD1MXhtFKnsbjK
-
Imai N, Miwa H, Shikami M et al (2009) Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor. Leuk Res 33:1650-1657
-
(2009)
Leuk Res
, vol.33
, pp. 1650-1657
-
-
Imai, N.1
Miwa, H.2
Shikami, M.3
-
45
-
-
0037815292
-
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
-
DOI 10.1083/jcb.200302047
-
Gerhardt H, Golding M, Fruttiger M et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163-1177 (Pubitemid 36870177)
-
(2003)
Journal of Cell Biology
, vol.161
, Issue.6
, pp. 1163-1177
-
-
Gerhardt, H.1
Golding, M.2
Fruttiger, M.3
Ruhrberg, C.4
Lundkvist, A.5
Abramsson, A.6
Jeltsch, M.7
Mitchell, C.8
Alitalo, K.9
Shima, D.10
Betsholtz, C.11
-
46
-
-
10644279947
-
Vascular endothelial growth factor and angiogenesis
-
DOI 10.1124/pr.56.4.3
-
Hoeben A, Landuyt B, Highley MS, Wildiers H, van Oosterom AT, de Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549-580 (Pubitemid 39658463)
-
(2004)
Pharmacological Reviews
, vol.56
, Issue.4
, pp. 549-580
-
-
Hoeben, A.1
Landuyt, B.2
Highley, M.S.3
Wildiers, H.4
Van Oosterom, A.T.5
De Bruijn, E.A.6
-
47
-
-
77954722597
-
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers
-
20606037 10.1158/1078-0432.CCR-09-2797 1:CAS:528:DC%2BC3cXovVansb4%3D
-
Smith NR, Baker D, James NH et al (2010) Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 16:3548-3561
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3548-3561
-
-
Smith, N.R.1
Baker, D.2
James, N.H.3
-
48
-
-
0032515047
-
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation
-
DOI 10.1074/jbc.273.46.30336
-
Gerber HP, McMurtrey A, Kowalski J et al (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343 (Pubitemid 28545503)
-
(1998)
Journal of Biological Chemistry
, vol.273
, Issue.46
, pp. 30336-30343
-
-
Gerber, H.-P.1
McMurtrey, A.2
Kowalski, J.3
Yan, M.4
Keyt, B.A.5
Dixit, V.6
Ferrara, N.7
-
49
-
-
33646107369
-
VEGF receptor signalling - In control of vascular function
-
16633338 10.1038/nrm1911 1:CAS:528:DC%2BD28XjslSktrc%3D
-
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7:359-371
-
(2006)
Nat Rev Mol Cell Biol
, vol.7
, pp. 359-371
-
-
Olsson, A.K.1
Dimberg, A.2
Kreuger, J.3
Claesson-Welsh, L.4
-
50
-
-
0033957420
-
Evidence of increased angiogenesis in patients with acute myeloid leukemia
-
Hussong JW, Rodgers GM, Shami PJ (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95:309-313 (Pubitemid 30017257)
-
(2000)
Blood
, vol.95
, Issue.1
, pp. 309-313
-
-
Hussong, J.W.1
Rodgers, G.M.2
Shami, P.J.3
-
51
-
-
0035009960
-
Increased bone marrow vascularization in patients with acute myeloid leukaemia: A possible role for vascular endothelial growth factor
-
DOI 10.1046/j.1365-2141.2001.02722.x
-
De Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E (2001) Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 113:296-304 (Pubitemid 32523131)
-
(2001)
British Journal of Haematology
, vol.113
, Issue.2
, pp. 296-304
-
-
De Bont, E.S.J.M.1
Rosati, S.2
Jacobs, S.3
Kamps, W.A.4
Vellenga, E.5
-
52
-
-
2542643823
-
Bone marrow microvessel density and it's prognostic significance in AML
-
DOI 10.1080/10428190410001663707
-
Rabitsch W, Sperr WR, Lechner K et al (2004) Bone marrow microvessel density and its prognostic significance in AML. Leuk Lymphoma 45:1369-1373 (Pubitemid 38701912)
-
(2004)
Leukemia and Lymphoma
, vol.45
, Issue.7
, pp. 1369-1373
-
-
Rabitsch, W.1
Sperr, W.R.2
Lechner, K.3
Chott, A.4
Prinz, E.5
Valent, P.6
Kalhs, P.7
-
53
-
-
0034655595
-
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
-
Padro T, Ruiz S, Bieker R et al (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95:2637-2644 (Pubitemid 30210544)
-
(2000)
Blood
, vol.95
, Issue.8
, pp. 2637-2644
-
-
Padro, T.1
Ruiz, S.2
Bieker, R.3
Burger, H.4
Steins, M.5
Kienast, J.6
Buchner, T.7
Berdel, W.E.8
Mesters, R.M.9
-
54
-
-
84865333261
-
High acute myeloid leukemia-derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow
-
10.1007/s13402-011-0017-9 1:CAS:528:DC%2BC3MXhtFWltbvJ
-
Weidenaar AC, Ter Elst A, Koopmans-Klein G et al (2011) High acute myeloid leukemia-derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow. Cell Oncol (Dordr) 34:289-296
-
(2011)
Cell Oncol (Dordr)
, vol.34
, pp. 289-296
-
-
Weidenaar, A.C.1
Ter Elst, A.2
Koopmans-Klein, G.3
-
55
-
-
84876665803
-
Patterns of bone marrow micro vessel morphology in AML and high risk MDS predict treatment outcome following intensive chemotherapy and bevacizumab
-
ASH abstract 1555
-
Weidenaar AC, Ter Elst A, van Montfort CAGM et al (2011) Patterns of bone marrow micro vessel morphology in AML and high risk MDS predict treatment outcome following intensive chemotherapy and bevacizumab. Blood, Suppl ASH abstract 1555
-
(2011)
Blood
, Issue.SUPPL.
-
-
Weidenaar, A.C.1
Ter Elst, A.2
Van Montfort Cagm3
-
56
-
-
0037114642
-
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo
-
DOI 10.1182/blood.V100.13.4622
-
Schuch G, Machluf M, Bartsch G Jr et al (2002) In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 100:4622-4628 (Pubitemid 35429707)
-
(2002)
Blood
, vol.100
, Issue.13
, pp. 4622-4628
-
-
Schuch, G.1
Machluf, M.2
Bartsch Jr., G.3
Nomi, M.4
Richard, H.5
Atala, A.6
Soker, S.7
-
57
-
-
0035499450
-
Stem cells find their niche
-
DOI 10.1038/35102160
-
Spradling A, Drummond-Barbosa D, Kai T (2001) Stem cells find their niche. Nature 414:98-104 (Pubitemid 33041633)
-
(2001)
Nature
, vol.414
, Issue.6859
, pp. 98-104
-
-
Spradling, A.1
Drummond-Barbosa, D.2
Kai, T.3
-
58
-
-
33644827383
-
Bone-marrow haematopoietic-stem-cell niches
-
DOI 10.1038/nri1779, PII N1779
-
Wilson A, Trumpp A (2006) Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 6:93-106 (Pubitemid 43361585)
-
(2006)
Nature Reviews Immunology
, vol.6
, Issue.2
, pp. 93-106
-
-
Wilson, A.1
Trumpp, A.2
-
59
-
-
21244463426
-
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells
-
DOI 10.1016/j.cell.2005.05.026, PII S0092867405005404
-
Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121:1109-1121 (Pubitemid 40884400)
-
(2005)
Cell
, vol.121
, Issue.7
, pp. 1109-1121
-
-
Kiel, M.J.1
Yilmaz, O.H.2
Iwashita, T.3
Yilmaz, O.H.4
Terhorst, C.5
Morrison, S.J.6
-
60
-
-
58149260269
-
Live-Animal tracking of individual haematopoietic stem/progenitor cells in their niche
-
10.1038/nature07434
-
Lo CC, Fleming HE, Wu JW et al (2009) Live-Animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457:92-96
-
(2009)
Nature
, vol.457
, pp. 92-96
-
-
Lo, C.C.1
Fleming, H.E.2
Wu, J.W.3
-
61
-
-
37449021071
-
Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche
-
DOI 10.1016/j.bbrc.2007.11.086, PII S0006291X07024801
-
Kubota Y, Takubo K, Suda T (2008) Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche. Biochem Biophys Res Commun 366:335-339 (Pubitemid 50016265)
-
(2008)
Biochemical and Biophysical Research Communications
, vol.366
, Issue.2
, pp. 335-339
-
-
Kubota, Y.1
Takubo, K.2
Suda, T.3
-
62
-
-
34248359065
-
Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia
-
DOI 10.1073/pnas.0701152104
-
Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104:5431-5436 (Pubitemid 47175697)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.13
, pp. 5431-5436
-
-
Parmar, K.1
Mauch, P.2
Vergilio, J.-A.3
Sackstein, R.4
Down, J.D.5
-
63
-
-
52449109941
-
Human mesenchymal stem cells as a stable source of VEGF-producing cells
-
18452238 10.1002/term.79 1:CAS:528:DC%2BD1MXls1Ght7o%3D
-
Kagiwada H, Yashiki T, Ohshima A, Tadokoro M, Nagaya N, Ohgushi H (2008) Human mesenchymal stem cells as a stable source of VEGF-producing cells. J Tissue Eng Regen Med 2:184-189
-
(2008)
J Tissue Eng Regen Med
, vol.2
, pp. 184-189
-
-
Kagiwada, H.1
Yashiki, T.2
Ohshima, A.3
Tadokoro, M.4
Nagaya, N.5
Ohgushi, H.6
-
64
-
-
34249722245
-
STAT3 mediates bone marrow mesenchymal stem cell VEGF production
-
DOI 10.1016/j.yjmcc.2007.04.010, PII S0022282807010036
-
Wang M, Zhang W, Crisostomo P et al (2007) STAT3 mediates bone marrow mesenchymal stem cell VEGF production. J Mol Cell Cardiol 42:1009-1015 (Pubitemid 46829204)
-
(2007)
Journal of Molecular and Cellular Cardiology
, vol.42
, Issue.6
, pp. 1009-1015
-
-
Wang, M.1
Zhang, W.2
Crisostomo, P.3
Markel, T.4
Meldrum, K.K.5
Fu, X.Y.6
Meldrum, D.R.7
-
65
-
-
0036217067
-
Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A
-
DOI 10.1210/en.143.4.1545
-
Deckers MM, van Bezooijen RL, van der Horst G et al (2002) Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143:1545-1553 (Pubitemid 34274386)
-
(2002)
Endocrinology
, vol.143
, Issue.4
, pp. 1545-1553
-
-
Deckers, M.M.L.1
Van Bezooijen, R.L.2
Van Geertje Horst, D.E.R.3
Hoogendam, J.4
Van Chris Bent, D.E.R.5
Papapoulos, S.E.6
Lowik, C.W.G.M.7
-
66
-
-
1642485905
-
Estrogen Regulates the Production of VEGF for Osteoclast Formation and Activity in op/op Mice
-
DOI 10.1359/JBMR.0301229
-
Kodama I, Niida S, Sanada M et al (2004) Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice. J Bone Miner Res 19:200-206 (Pubitemid 38116733)
-
(2004)
Journal of Bone and Mineral Research
, vol.19
, Issue.2
, pp. 200-206
-
-
Kodama, I.1
Niida, S.2
Sanada, M.3
Yoshiko, Y.4
Tsuda, M.5
Maeda, N.6
Ohama, K.7
-
67
-
-
42949153257
-
Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF
-
DOI 10.1002/path.2319
-
Knowles HJ, Athanasou NA (2008) Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol 215:56-66 (Pubitemid 351619876)
-
(2008)
Journal of Pathology
, vol.215
, Issue.1
, pp. 56-66
-
-
Knowles, H.J.1
Athanasou, N.A.2
-
68
-
-
45149117132
-
VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism
-
18359770 10.1074/jbc.M708055200 1:CAS:528:DC%2BD1cXltlKjsrk%3D
-
Zhang Q, Guo R, Lu Y et al (2008) VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem 283:13491-13499
-
(2008)
J Biol Chem
, vol.283
, pp. 13491-13499
-
-
Zhang, Q.1
Guo, R.2
Lu, Y.3
-
69
-
-
79551620014
-
Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo
-
21131587 10.1182/blood-2010-05-282855 1:CAS:528:DC%2BC3MXit1KksLo%3D
-
Lymperi S, Ersek A, Ferraro F, Dazzi F, Horwood NJ (2011) Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood 117:1540-1549
-
(2011)
Blood
, vol.117
, pp. 1540-1549
-
-
Lymperi, S.1
Ersek, A.2
Ferraro, F.3
Dazzi, F.4
Horwood, N.J.5
-
70
-
-
35948984135
-
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
-
DOI 10.1038/nbt1350, PII NBT1350
-
Ishikawa F, Yoshida S, Saito Y et al (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25:1315-1321 (Pubitemid 350076512)
-
(2007)
Nature Biotechnology
, vol.25
, Issue.11
, pp. 1315-1321
-
-
Ishikawa, F.1
Yoshida, S.2
Saito, Y.3
Hijikata, A.4
Kitamura, H.5
Tanaka, S.6
Nakamura, R.7
Tanaka, T.8
Tomiyama, H.9
Saito, N.10
Fukata, M.11
Miyamoto, T.12
Lyons, B.13
Ohshima, K.14
Uchida, N.15
Taniguchi, S.16
Ohara, O.17
Akashi, K.18
Harada, M.19
Shultz, L.D.20
more..
-
71
-
-
33845540617
-
Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice
-
DOI 10.1038/sj.leu.2404432, PII 2404432
-
Ninomiya M, Abe A, Katsumi A et al (2007) Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 21:136-142 (Pubitemid 44921844)
-
(2007)
Leukemia
, vol.21
, Issue.1
, pp. 136-142
-
-
Ninomiya, M.1
Abe, A.2
Katsumi, A.3
Xu, J.4
Ito, M.5
Arai, F.6
Suda, T.7
Ito, M.8
Kiyoi, H.9
Kinoshita, T.10
Naoe, T.11
-
72
-
-
34249721065
-
Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity [6]
-
DOI 10.1038/sj.leu.2404632, PII 2404632
-
Zahiragic L, Schliemann C, Bieker R et al (2007) Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 21:1310-1312 (Pubitemid 46831824)
-
(2007)
Leukemia
, vol.21
, Issue.6
, pp. 1310-1312
-
-
Zahiragic, L.1
Schliemann, C.2
Bieker, R.3
Thoennissen, N.H.4
Burow, K.5
Kramer, C.6
Zuhlsdorf, M.7
Berdel, W.E.8
Mesters, R.M.9
-
73
-
-
2542547507
-
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-β -D-Arabinofuranosylcytosine, mitoxantrone, and bevacizumab
-
DOI 10.1158/1078-0432.CCR-03-0627
-
Karp JE, Gojo I, Pili R et al (2004) Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-Arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 10:3577-3585 (Pubitemid 38697590)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.11
, pp. 3577-3585
-
-
Karp, J.E.1
Gojo, I.2
Pili, R.3
Gocke, C.D.4
Greer, J.5
Guo, C.6
Qian, D.7
Morris, L.8
Tidwell, M.9
Chen, H.10
Zwiebel, J.11
-
74
-
-
33744482540
-
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome
-
DOI 10.1038/sj.leu.2404213, PII 2404213
-
Roboz GJ, Giles FJ, List AF et al (2006) Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20:952-957 (Pubitemid 43797284)
-
(2006)
Leukemia
, vol.20
, Issue.6
, pp. 952-957
-
-
Roboz, G.J.1
Giles, F.J.2
List, A.F.3
Cortes, J.E.4
Carlin, R.5
Kowalski, M.6
Bilic, S.7
Masson, E.8
Rosamilia, M.9
Schuster, M.W.10
Laurent, D.11
Feldman, E.J.12
-
75
-
-
0035412371
-
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
-
11418488 10.1182/blood.V98.1.241 1:CAS:528:DC%2BD3MXkvFSls70%3D
-
Mesters RM, Padro T, Bieker R et al (2001) Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 98:241-243
-
(2001)
Blood
, vol.98
, pp. 241-243
-
-
Mesters, R.M.1
Padro, T.2
Bieker, R.3
-
76
-
-
0141993064
-
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
-
DOI 10.1182/blood-2002-10-2998
-
Fiedler W, Mesters R, Tinnefeld H et al (2003) A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102:2763-2767 (Pubitemid 37248845)
-
(2003)
Blood
, vol.102
, Issue.8
, pp. 2763-2767
-
-
Fiedler, W.1
Mesters, R.2
Tinnefeld, H.3
Loges, S.4
Staib, P.5
Duhrsen, U.6
Flasshove, M.7
Ottmann, O.G.8
Jung, W.9
Cavalli, F.10
Kuse, R.11
Thomalla, J.12
Serve, H.13
O'Farrell, A.M.14
Jacobs, M.15
Brega, N.M.16
Scigalla, P.17
Hossfeld, D.K.18
Berdel, W.E.19
-
77
-
-
19944431093
-
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
-
DOI 10.1182/blood-2004-05-1846
-
Fiedler W, Serve H, Dohner H et al (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105:986-993 (Pubitemid 40170865)
-
(2005)
Blood
, vol.105
, Issue.3
, pp. 986-993
-
-
Fiedler, W.1
Serve, H.2
Dohner, H.3
Schwittay, M.4
Ottmann, O.G.5
O'Farrell, A.-M.6
Bello, C.L.7
Allred, R.8
Manning, W.C.9
Cherrington, J.M.10
Louie, S.G.11
Hong, W.12
Brega, N.M.13
Massimini, G.14
Scigalla, P.15
Berdel, W.E.16
Hossfeld, D.K.17
-
78
-
-
33744553087
-
The anti-Angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
-
DOI 10.1016/j.leukres.2005.10.024, PII S0145212605004248
-
Giles FJ, Bellamy WT, Estrov Z et al (2006) The anti-Angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res 30:801-811 (Pubitemid 43816694)
-
(2006)
Leukemia Research
, vol.30
, Issue.7
, pp. 801-811
-
-
Giles, F.J.1
Bellamy, W.T.2
Estrov, Z.3
O'Brien, S.M.4
Verstovsek, S.5
Ravandi, F.6
Beran, M.7
Bycott, P.8
Pithavala, Y.9
Steinfeldt, H.10
Reich, S.D.11
List, A.F.12
Yee, K.W.L.13
-
79
-
-
69249221392
-
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation
-
19389879 10.1182/blood-2009-03-208298 1:CAS:528:DC%2BD1MXotlWru74%3D
-
Metzelder S, Wang Y, Wollmer E et al (2009) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113:6567-6571
-
(2009)
Blood
, vol.113
, pp. 6567-6571
-
-
Metzelder, S.1
Wang, Y.2
Wollmer, E.3
-
80
-
-
78049426367
-
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3
-
20733134 10.1200/JCO.2010.28.9678 1:CAS:528:DC%2BC3cXhtl2ks7vL
-
Fischer T, Stone RM, Deangelo DJ et al (2010) Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28:4339-4345
-
(2010)
J Clin Oncol
, vol.28
, pp. 4339-4345
-
-
Fischer, T.1
Stone, R.M.2
Deangelo, D.J.3
-
81
-
-
84876674315
-
Phase II study of AZD2171 for the treatment of patients with acute myelogenous leukemia
-
ASCO, Suppl abstract 6574
-
Juckett M, LaPlant B, Flynn PJ et al (2011) Phase II study of AZD2171 for the treatment of patients with acute myelogenous leukemia. J Clin Oncol 29, ASCO, Suppl abstract 6574
-
(2011)
J Clin Oncol
, vol.29
-
-
Juckett, M.1
Laplant, B.2
Flynn, P.J.3
-
82
-
-
71849097154
-
Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis
-
19883397 10.1111/j.1600-0854.2009.01001.x 1:CAS:528:DC%2BC3cXnsVKg
-
Bruns AF, Herbert SP, Odell AF et al (2010) Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. Traffic 11:161-174
-
(2010)
Traffic
, vol.11
, pp. 161-174
-
-
Bruns, A.F.1
Herbert, S.P.2
Odell, A.F.3
|